Polidocanol
- Generic Name
- Polidocanol
- Brand Names
- Asclera, Varithena
- Drug Type
- Small Molecule
- Chemical Formula
- C30H62O10
- CAS Number
- 9002-92-0
- Unique Ingredient Identifier
- 0AWH8BFG9A
- Background
Polidocanol is a sclerosing agent indicated to treat uncomplicated spider veins (varicose veins ≤1 mm in diameter) and uncomplicated reticular veins (varicose veins 1 to 3 mm in diameter) in the lower extremity. It is marketed under the brand names Asclera and Varithena. The formula for Polidocanol has the structural formula C12H25(OCH2CH2)nOH, a mean extent...
- Indication
Polidocanol is a sclerosing agent indicated to treat uncomplicated spider veins and uncomplicated reticular veins in the lower extremity.
- Associated Conditions
- Pain caused by Teething, Incompetent accessory saphenous veins, Incompetent great saphenous veins, Superficial venous incompetence, Uncomplicated veins 1 to 3 mm in diameter reticular veins, Uncomplicated veins <1 mm in diameter Spider Veins, Varicosities of the great saphenous vein
- Associated Therapies
- -
Efficacy of Skin Cooling in Reducing Pain Associated With Non-invasive Treatments of Neurofibromatosis Type 1 Cutaneous Neurofibromas
- Conditions
- Interventions
- First Posted Date
- 2023-11-15
- Last Posted Date
- 2024-02-09
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT06132165
- Locations
- 🇺🇸
Wellman Center for Photomedicine, Boston, Massachusetts, United States
Comparative Study of Polidocanol and Absolute Alcohol for Percutaneous us Guided Treatment of Benign Thyroid Cyst
- Conditions
- Interventions
- First Posted Date
- 2023-04-05
- Last Posted Date
- 2023-04-05
- Lead Sponsor
- Assiut University
- Target Recruit Count
- 30
- Registration Number
- NCT05798936
Effect of VarIthena on Wound Healing in Venous Leg Ulcers (VLU)
- Conditions
- First Posted Date
- 2017-08-22
- Last Posted Date
- 2021-12-14
- Lead Sponsor
- Boston Scientific Corporation
- Target Recruit Count
- 76
- Registration Number
- NCT03257254
- Locations
- 🇺🇸
Pines Clinical Research, Aventura, Florida, United States
🇨🇦Oakville Vascular, Oakville, Ontario, Canada
🇺🇸OhioHealth Research, Columbus, Ohio, United States
An Assessment of Intra-lesional 3% Polidocanol Solution in the Treatment of Digital Myxoid Cyst
- Conditions
- Interventions
- First Posted Date
- 2014-06-03
- Last Posted Date
- 2024-05-30
- Lead Sponsor
- University of Edinburgh
- Target Recruit Count
- 10
- Registration Number
- NCT02154789
- Locations
- 🇬🇧
Queen Margaret Hospital, Whitefield Road, Dunfermline, Fife, United Kingdom
🇬🇧Department of Dermatology, Royal Infirmary, Edinburgh, Midlothian, United Kingdom
TENDOSHOCK-2010 Combination Therapy for Athletic Tendinopathies
- Conditions
- Interventions
- Drug: PolidocanolDevice: Focused extracorporeal shock wave therapyDrug: Topical NOBehavioral: Painful eccentric training in Achilles tendinopathyBehavioral: Painful eccentric training for patella tendinopathy on 25° decline boardBehavioral: Painful eccentric training for elbow tendinopathy using Thera-Band Flex-Bar
- First Posted Date
- 2010-08-20
- Last Posted Date
- 2010-08-20
- Lead Sponsor
- Hannover Medical School
- Target Recruit Count
- 114
- Registration Number
- NCT01185951
- Locations
- 🇩🇪
Hannover Medical School, Plastic, Hand and Reconstructive Surgery, Hannover, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.